Alnylam guides up on collaboration, royalty revenue

 2023 Financial Guidance 

Full year 2023 financial guidance has been updated as follows:

		Provided 2/23/20231	Updated 11/2/2023
Combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO1		$1,200 million - $1,285 million	Unchanged
Net Product Revenue Growth vs. 2022 at reported FX rates1		34% to 44%	Unchanged
Net Product Revenue Growth vs. 2022 at CER*		34% to 44%	Unchanged
Net revenues from collaborations and royalties		$100 million - $175 million	$575 million - $625 million
GAAP R&D and SG&A expenses		$1,790 million - $1,885 million	Unchanged
Non-GAAP R&D and SG&A expenses2		$1,575 million - $1,650 million	Unchanged
1 Uses December 31, 2022 FX rates including: 1 EUR = 1.07 USD and 1 USD = 131 JPY
2 Excludes $215 - $235 million of stock-based compensation expense from estimated GAAP R&D and SG&A expenses
*CER = Constant Exchange Rate, representing growth calculated as if the exchange rates had remained unchanged from those used in the twelve months ended December 31, 2022. CER is a Non-GAAP measure. https://www.biospace.com/article/releases/alnylam-pharmaceuticals-reports-third-quarter-2023-financial-results-and-highlights-recent-period-activity/